Industry Analysts Just Upgraded Their Neuren Pharmaceuticals Limited (ASX:NEU) Revenue Forecasts By 15%

Neuren Pharmaceuticals Limited (ASX:NEU) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that Neuren Pharmaceuticals will make substantially more sales than they'd previously expected. The market may be pricing in some blue sky too, with the share price gaining 14% to AU$23.24 in the last 7 days. Could this upgrade be enough to drive the stock even higher?

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

After this upgrade, Neuren Pharmaceuticals' five analysts are now forecasting revenues of AU$133m in 2026. This would be a major 91% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of AU$116m in 2026. The consensus has definitely become more optimistic, showing a solid increase in revenue forecasts.

Check out our latest analysis for Neuren Pharmaceuticals

We'd point out that there was no major changes to their price target of AU$27.03, suggesting the latest estimates were not enough to shift their view on the value of the business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Neuren Pharmaceuticals' past performance and to peers in the same industry. It's clear from the latest estimates that Neuren Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 267% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 34% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 32% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Neuren Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. Analysts also expect revenues to grow faster than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Neuren Pharmaceuticals.

Analysts are clearly in love with Neuren Pharmaceuticals at the moment, but before diving in - you should be aware that we've identified some warning flags with the business, such as its declining profit margins. You can learn more, and discover the 1 other concern we've identified, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.